BMS-986345
Unresectable Melanoma
John KirkwoodPhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Unresectable Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lifileucel Iovance Biotherapeutics, Inc. | Phase 3 | BB |
Tocilizumab University of Southern California | Phase 2 | B |
Iov-3001 Iovance Biotherapeutics, Inc. | Phase 1/2 | CCC |
Eb-Dtkn-401 Allogeneic Dual-Target Cspg4/Gd2 Car-Nk Cells Beijing Biotech | Phase 1/2 | CCC |
Duvelisib John Kirkwood | Phase 1/2 | CC |
View all 19 →
Same molecule, other indications
BMS-986345 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →